Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.

Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...

US clinical-stage biotech Q32 Bio (Nasdaq: QTTB) saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed ...

Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Q32 Bio (QTTB – Research Report), with a price target of ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Q32 Bio (QTTB – Research Report) today and set a price target of $20.00.

Stitch Fix reported a quarterly loss of 5 cents per share which beat the analyst consensus estimate of a loss of 13 cents per ...

Oppenheimer slashed its price target on Q32 Bio Inc (NASDAQ:QTTB) after the firm released mixed results from two ongoing phase 2 trials for its Bempikibart treatment.

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the ...

Equities researchers at BMO Capital Markets began coverage on shares of Q32 Bio (NASDAQ:QTTB – Get Free Report) in a research note issued on Friday, Marketbeat Ratings reports. The brokerage set an ...